Future PE of 20x Signals Promising Growth for Novo Nordisk

Published
28 Jan 25
Updated
30 Jul 25
Bejgal's Fair Value
US$69.18
17.6% undervalued intrinsic discount
30 Jul
US$56.98
Loading
1Y
-58.4%
7D
8.7%

Author's Valuation

US$69.2

17.6% undervalued intrinsic discount

Bejgal's Fair Value

Shared on30 Jul 25
Fair value Decreased 3.26%

Bejgal has increased revenue growth from 5.0% to 11.1% and decreased future PE multiple from 25.0x to 20.0x.

Shared on29 Jul 25
Fair value Decreased 15%

Bejgal has decreased revenue growth from 12.2% to 5.0%, decreased future PE multiple from 30.0x to 25.0x and decreased shares outstanding growth rate from 0.1% to -0.0%.

Shared on20 May 25
Fair value Increased 23%

Bejgal has decreased revenue growth from 16.9% to 12.2% and increased future PE multiple from 25.0x to 30.0x.

Shared on15 Mar 25
Fair value Decreased 24%

Bejgal has decreased revenue growth from 18.9% to 16.9%.

Shared on14 Mar 25
Fair value Increased 5.38%

Bejgal made no meaningful changes to valuation assumptions.

Shared on09 Mar 25
Fair value Decreased 16%

Bejgal has decreased future PE multiple from 30.0x to 25.0x.

Shared on11 Feb 25
Fair value Decreased 4.30%

Bejgal made no meaningful changes to valuation assumptions.

Shared on29 Jan 25
Fair value Decreased 0.19%

Bejgal made no meaningful changes to valuation assumptions.